secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nordicus Partners Corp (NORD)
CIK:        0001011060
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001493152-24-044999
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 2.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nordicus acquires remaining ~5% of Orocidin, making it wholly owned subsidiary
------------------------------------------------------------------------------

- Acquired 29,663 Orocidin shares (5.34% of outstanding) for 200,000 restricted common shares.
- Transaction closed November 12, 2024; Orocidin now 100% owned by Nordicus.
- Orocidin is a clinical-stage biopharma developing periodontitis therapies.
- Follows Nordicus' May 2024 purchase of 95% of Orocidin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1011060/000149315224044999/0001493152-24-044999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1011060/000149315224044999/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer